has O O O O
long O O O O
presented O O O O
treatment O O O O
challenges, O O O O
but O O O O
evolving O O O O
literature O O O O
and O O O O
new O O O O
data O O O O
show O O O O
significant O O O O
promise O O O O
for O O O O
this O O O O
patient O O O O
population, O O O O
according O O O O
to O O O O
presenter O O O O
Erika O O O O
P. O O O O
Hamilton, O O O O
MD, O O O O
in O O O O
a O O O O
session O O O O
at O O O O
the O O O O
[2023 O O O O
Community O O O O
Oncology O O O O
Alliance O O O O
(COA) O O O O
meeting](https://www.pharmacytimes.com/conference/coa). O O O O
Drugs O O O O
govitecan O O O O
(SG), O O O O
and O O O O
datopotamab O O O O
deruxtecan O O O O
(Dato-DXd) O O O O
all O O O O
have O O O O
growing O O O O
bodies O O O O
of O O O O
evidence O O O O
illustrating O O O O
which O O O O
patients O O O O
are O O O O
most O O O O
likely O O O O
to O O O O
benefit O O O O
and O O O O
in O O O O
which O O O O
settings. O O O O
For Reason 3 O O
example, Reason 3 O O
the Reason 3 O O
KEYNOTE Reason 3 O O
355 Reason 3 O O
trial Reason 3 O O
of Reason 3 O O
pembrolizumab Reason 3 O O
in Reason 3 O O
first-line Reason 3 O O
TNBC Reason 3 O O
provided Reason 3 O O
insight Reason 3 O O
into Reason 3 O O
both Reason 3 O O
the Reason 3 O O
setting Reason 3 O O
and Reason 3 O O
metastatic Reason 3 O O
site, Reason 3 O O
as Reason 3 O O
well Reason 3 O O
as Reason 3 O O
how Reason 3 O O
much Reason 3 O O
these Reason 3 O O
considerations Reason 3 O O
matter, Reason 3 O O
according Reason 3 O O
to Reason 3 O O
Hamilton. Reason 3 O O
In Reason 3 O O
that Reason 3 O O
trial, Reason 3 O O
three-quarters Reason 3 O O
of Reason 3 O O
the Reason 3 O O
patients Reason 3 O O
had Reason 3 O O
programmed Reason 3 O O
death-ligand Reason 3 O O
1 Reason 3 O O
(PD-L1) Reason 3 O O
expression; Reason 3 O O
however, Reason 3 O O
with Reason 3 O O
a Reason 3 O O
more Reason 3 O O
stringent Reason 3 O O
cutoff Reason 3 O O
of Reason 3 O O
a Reason 3 O O
combined Reason 3 O O
positive Reason 3 O O
score Reason 3 O O
(CPS) Reason 3 O O
of Reason 3 O O
at Reason 3 O O
least Reason 3 O O
10, Reason 3 O O
that Reason 3 O O
number Reason 3 O O
fell Reason 3 O O
to Reason 3 O O
35% Reason 3 O O
to Reason 3 O O
40%. Reason 3 O O
In Reason 3 O O
the Reason 3 O O
intent-to-treat Reason 3 O O
(ITT) Reason 3 O O
population, Reason 3 O O
there Reason 3 O O
was Reason 3 O O
no Reason 3 O O
significant Reason 3 O O
benefit, Reason 3 O O
and Reason 3 O O
this Reason 3 O O
was Reason 3 O O
the Reason 3 O O
same Reason 3 O O
in Reason 3 O O
the Reason 3 O O
CPS Reason 3 O O
cutoff Reason 3 O O
of Reason 3 O O
1 Reason 3 O O
or Reason 3 O O
greater. Reason 3 O O
However, Reason 3 O O
in Reason 3 O O
those Reason 3 O O
with Reason 3 O O
a Reason 3 O O
CPS Reason 3 O O
score Reason 3 O O
of Reason 3 O O
at Reason 3 O O
least Reason 3 O O
10, Reason 3 O O
there Reason 3 O O
was Reason 3 O O
a Reason 3 O O
significant Reason 3 O O
benefit Reason 3 O O
in Reason 3 O O
progression-free Reason 3 O O
survival Reason 3 O O
(PFS) Reason 3 O O
with Reason 3 O O
the Reason 3 O O
addition Reason 3 O O
of Reason 3 O O
pembrolizumab. Reason 3 O O
Based Reason 3 O O
on Reason 3 O O
this, Reason 3 O O
the Reason 3 O O
FDA Reason 3 O O
approved Reason 3 O O
pembrolizumab Reason 3 O O
plus Reason 3 O O
chemotherapy Reason 3 O O
for Reason 3 O O
metastatic Reason 3 O O
TNBC Reason 3 O O
with Reason 3 O O
a Reason 3 O O
CPS Reason 3 O O
score Reason 3 O O
of Reason 3 O O
at Reason 3 O O
least Reason 3 O O
10. Reason 3 O O
Hamilton Reason 3 O O
noted Reason 3 O O
that Reason 3 O O
immune-mediated Reason 3 O O
adverse Reason 3 O O
events Reason 3 O O
(AEs) Reason 3 O O
are Reason 3 O O
the Reason 3 O O
main Reason 3 O O
reason Reason 3 O O
that Reason 3 O O
this Reason 3 O O
is Reason 3 O O
not Reason 3 O O
indicated Reason 3 O O
in Reason 3 O O
patients Reason 3 O O
with Reason 3 O O
a Reason 3 O O
CPS Reason 3 O O
score Reason 3 O O
of Reason 3 O O
less Reason 3 O O
than Reason 3 O O
10. Reason 3 O O
These Reason 3 O O
can Reason 3 O O
include Reason 3 O O
hypothyroidism, Reason 3 O O
hyperthyroidism, Reason 3 O O
pneumonitis, Reason 3 O O
colitis, Reason 3 O O
and Reason 3 O O
severe Reason 3 O O
skin Reason 3 O O
reactions, Reason 3 O O
all Reason 3 O O
of Reason 3 O O
which Reason 3 O O
tend Reason 3 O O
to Reason 3 O O
occur Reason 3 O O
in Reason 3 O O
approximately Reason 3 O O
one-quarter Reason 3 O O
of Reason 3 O O
patients Reason 3 O O
receiving Reason 3 O O
pembrolizumab, Reason 3 O O
Hamilton Reason 3 O O
said. Reason 3 O O
Hamilton Reason 5 O O
noted Reason 5 O O
that Reason 5 O O
the Reason 5 O O
KEYNOTE Reason 5 O O
355 Reason 5 O O
trial Reason 5 O O
showed Reason 5 O O
no Reason 5 O O
real Reason 5 O O
difference Reason 5 O O
in Reason 5 O O
overall Reason 5 O O
survival Reason 5 O O
(OS) Reason 5 O O
in Reason 5 O O
the Reason 5 O O
ITT Reason 5 O O
group Reason 5 O O
and Reason 5 O O
the Reason 5 O O
patient Reason 5 O O
population Reason 5 O O
with Reason 5 O O
a Reason 5 O O
CPS Reason 5 O O
score Reason 5 O O
of Reason 5 O O
at Reason 5 O O
least Reason 5 O O
1. Reason 5 O O
However, Reason 5 O O
improvement Reason 5 O O
was Reason 5 O O
seen Reason 5 O O
in Reason 5 O O
those Reason 5 O O
with Reason 5 O O
a Reason 5 O O
CPS Reason 5 O O
score Reason 5 O O
of Reason 5 O O
at Reason 5 O O
least Reason 5 O O
10, Reason 5 O O
going Reason 5 O O
from Reason 5 O O
16.1 Reason 5 O O
months Reason 5 O O
to Reason 5 O O
23 Reason 5 O O
months. Reason 5 O O
Hamilton Reason 5 O O
did Reason 5 O O
point Reason 5 O O
out, Reason 5 O O
however, Reason 5 O O
that Reason 5 O O
this Reason 5 O O
trial Reason 5 O O
did Reason 5 O O
not Reason 5 O O
include Reason 5 O O
the Reason 5 O O
use Reason 5 O O
of Reason 5 O O
antibody Reason 5 O O
drug Reason 5 O O
conjugates Reason 5 O O
(ADCs). Reason 5 O O
"I Reason 5 O O
think Reason 5 O O
we Reason 5 O O
really Reason 5 O O
are Reason 5 O O
doing Reason 5 O O
better Reason 5 O O
than Reason 5 O O
this Reason 5 O O
now, Reason 5 O O
but Reason 5 O O
still, Reason 5 O O
triple-negative Reason 5 O O
has Reason 5 O O
the Reason 5 O O
worst Reason 5 O O
prognosis Reason 5 O O
or Reason 5 O O
our Reason 5 O O
three Reason 5 O O
[breast Reason 5 O O
cancer] Reason 5 O O
types," Reason 5 O O
Hamilton Reason 5 O O
said. Reason 5 O O
ADCs O O O O
have O O O O
significant O O O O
potential, O O O O
an O O O O
example O O O O
of O O O O
which O O O O
is O O O O
SG. O O O O
The O O O O
ASCENT O O O O
trial O O O O
investigated O O O O
SG O O O O
in O O O O
the O O O O
third- O O O O
and O O O O
fourth-line O O O O
settings, O O O O
which O O O O
showed O O O O
a O O O O
5.6-month O O O O
PFS O O O O
with O O O O
SG O O O O
versus O O O O
1.7 O O O O
months O O O O
with O O O O
chemotherapy O O O O
only. O O O O
In O O O O
April O O O O
2021, O O O O
Hamilton O O O O
said O O O O
the O O O O
FDA O O O O
granted O O O O
regular O O O O
approval O O O O
to O O O O
SG O O O O
for O O O O
patients O O O O
with O O O O
metastatic O O O O
PFS O O O O
who O O O O
have O O O O
received O O O O
2 O O O O
or O O O O
more O O O O
prior O O O O
systemic O O O O
therapies, O O O O
at O O O O
least O O O O
1 O O O O
of O O O O
which O O O O
was O O O O
for O O O O
metastatic O O O O
disease. O O O O
Additionally, O O O O
OS O O O O
was O O O O
increased O O O O
by O O O O
up O O O O
to O O O O
a O O O O
year O O O O
in O O O O
patients O O O O
receiving O O O O
SG O O O O
in O O O O
the O O O O
ASCENT O O O O
trial, O O O O
demonstrating O O O O
an O O O O
improvement O O O O
of O O O O
approximately O O O O
6 O O O O
months. O O O O
Hamilton O O O O
said O O O O
these O O O O
findings O O O O
raised O O O O
questions O O O O
about O O O O
whether O O O O
clinicians O O O O
should O O O O
test O O O O
for O O O O
Trop2 O O O O
expression. O O O O
"Patients O O O O
that O O O O
have O O O O
high O O O O
Trop2 O O O O
[expression] O O O O
certainly O O O O
get O O O O
great O O O O
benefit O O O O
from O O O O
sacituzumab, O O O O
but O O O O
even O O O O
those O O O O
patients O O O O
that O O O O
have O O O O
low O O O O
expression—although O O O O
they O O O O
don't O O O O
do O O O O
as O O O O
well—are O O O O
still O O O O
outperforming O O O O
chemotherapy," O O O O
Hamilton O O O O
explained. O O O O
"And O O O O
so, O O O O
this O O O O
really O O O O
led O O O O
to O O O O
the O O O O
idea O O O O
that O O O O
we O O O O
don't O O O O
need O O O O
to O O O O
be O O O O
testing O O O O
for O O O O
Trop2." O O O O
Several Reason 3 O O
upcoming Reason 3 O O
trials Reason 3 O O
are Reason 3 O O
aiming Reason 3 O O
to Reason 3 O O
further Reason 3 O O
the Reason 3 O O
data Reason 3 O O
supporting Reason 3 O O
SG, Reason 3 O O
including Reason 3 O O
the Reason 3 O O
ASCENT-03 Reason 3 O O
trial Reason 3 O O
examining Reason 3 O O
it Reason 3 O O
in Reason 3 O O
the Reason 3 O O
first Reason 3 O O
line Reason 3 O O
setting Reason 3 O O
for Reason 3 O O
metastatic Reason 3 O O
TNBC Reason 3 O O
and Reason 3 O O
the Reason 3 O O
ASCENT-04 Reason 3 O O
trial Reason 3 O O
of Reason 3 O O
SG Reason 3 O O
in Reason 3 O O
addition Reason 3 O O
to Reason 3 O O
immunotherapy Reason 3 O O
in Reason 3 O O
the Reason 3 O O
first-line Reason 3 O O
setting. Reason 3 O O
With Reason 3 O O
these Reason 3 O O
ongoing Reason 3 O O
trials, Reason 3 O O
Hamilton Reason 3 O O
said Reason 3 O O
she Reason 3 O O
anticipates Reason 3 O O
that Reason 3 O O
SG Reason 3 O O
will Reason 3 O O
eventually Reason 3 O O
move Reason 3 O O
into Reason 3 O O
the Reason 3 O O
first-line Reason 3 O O
setting. Reason 3 O O
Dato-DXd O O O O
is O O O O
another O O O O
promising O O O O
Trop2-targeting O O O O
ADC. O O O O
In Reason 4 O O
the Reason 4 O O
TROPION Reason 4 O O
PanTumor01 Reason 4 O O
study, Reason 4 O O
treatment Reason 4 O O
with Reason 4 O O
Dato-DXd Reason 4 O O
showed Reason 4 O O
encouraging Reason 4 O O
OS Reason 4 O O
data, Reason 4 O O
with Reason 4 O O
an Reason 4 O O
overall Reason 4 O O
response Reason 4 O O
rate Reason 4 O O
of Reason 4 O O
32% Reason 4 O O
in Reason 4 O O
all Reason 4 O O
patients Reason 4 O O
and Reason 4 O O
44% Reason 4 O O
in Reason 4 O O
topoisomerase Reason 4 O O
I Reason 4 O O
inhibitor-naïve Reason 4 O O
patients. Reason 4 O O
Additionally, Reason 4 O O
the Reason 4 O O
median Reason 4 O O
duration Reason 4 O O
of Reason 4 O O
response Reason 4 O O
was Reason 4 O O
16.8 Reason 4 O O
in Reason 4 O O
both Reason 4 O O
treatment Reason 4 O O
arms; Reason 4 O O
the Reason 4 O O
median Reason 4 O O
PFS Reason 4 O O
was Reason 4 O O
4.4 Reason 4 O O
months Reason 4 O O
in Reason 4 O O
all Reason 4 O O
patients Reason 4 O O
and Reason 4 O O
7.3 Reason 4 O O
months Reason 4 O O
in Reason 4 O O
topoisomerase Reason 4 O O
I Reason 4 O O
inhibitor-naïve Reason 4 O O
patients; Reason 4 O O
and Reason 4 O O
the Reason 4 O O
median Reason 4 O O
OS Reason 4 O O
was Reason 4 O O
a Reason 4 O O
little Reason 4 O O
over Reason 4 O O
1 Reason 4 O O
year Reason 4 O O
in Reason 4 O O
both Reason 4 O O
groups. Reason 4 O O
The O O O O
BEGONIA O O O O
trial O O O O
is O O O O
also O O O O
investigating O O O O
Dato-DXd O O O O
in O O O O
addition O O O O
to O O O O
durvalumab O O O O
and O O O O
has O O O O
shown O O O O
impressive O O O O
tumor O O O O
shrinkage. O O O O
Hamilton O O O O
said O O O O
82% O O O O
of O O O O
patients O O O O
were O O O O
still O O O O
on O O O O
treatment O O O O
at O O O O
the O O O O
time O O O O
of O O O O
data O O O O
disclosure, O O O O
with O O O O
a O O O O
follow-up O O O O
of O O O O
about O O O O
7 O O O O
months. O O O O
This O O O O
treatment O O O O
also O O O O
looks O O O O
quite O O O O
durable O O O O
in O O O O
the O O O O
first-line O O O O
setting, O O O O
and O O O O
response O O O O
was O O O O
seen O O O O
in O O O O
both O O O O
PD-L1 O O O O
high O O O O
and O O O O
PD-L1 O O O O
low O O O O
tumors. O O O O
Finally, O O O O
the O O O O
DAISY O O O O
trial O O O O
is O O O O
examining O O O O
the O O O O
efficacy O O O O
of O O O O
trastuzumab O O O O
deruxtecan O O O O
(T-DXd) O O O O
in O O O O
patients O O O O
with O O O O
human O O O O
epidermal O O O O
growth O O O O
factor O O O O
receptor O O O O
2 O O O O
(HER2)-low O O O O
breast O O O O
cancer, O O O O
and O O O O
particularly O O O O
those O O O O
with O O O O
an O O O O
immunohistochemistry O O O O
score O O O O
of O O O O
0 O O O O
or O O O O
greater. O O O O
Response O O O O
rates O O O O
are O O O O
encouraging, O O O O
with O O O O
a O O O O
median O O O O
PFS O O O O
of O O O O
4.5 O O O O
months O O O O
in O O O O
the O O O O
hormone O O O O
receptor O O O O
(HR)-positive O O O O
group O O O O
and O O O O
2.1 O O O O
months O O O O
in O O O O
the O O O O
HR-negative O O O O
group. O O O O
Additionally, O O O O
the O O O O
trial O O O O
has O O O O
seen O O O O
a O O O O
median O O O O
OS O O O O
of O O O O
11.6 O O O O
months O O O O
in O O O O
the O O O O
treatment O O O O
arm. O O O O
Next, O O O O
Hamilton O O O O
discussed O O O O
developments O O O O
in O O O O
early O O O O
breast O O O O
cancer. O O O O
The O O O O
KEYNOTE O O O O
522 O O O O
study O O O O
investigated O O O O
pembrolizumab O O O O
for O O O O
this O O O O
patient O O O O
population, O O O O
including O O O O
a O O O O
broad O O O O
population O O O O
of O O O O
anyone O O O O
with O O O O
at O O O O
least O O O O
a O O O O
2 O O O O
cm O O O O
tumor O O O O
or O O O O
any O O O O
known O O O O
positivity. O O O O
Notably, O O O O
the O O O O
primary O O O O
endpoint, O O O O
pathologic O O O O
complete O O O O
response, O O O O
showed O O O O
an O O O O
improvement O O O O
from O O O O
51% O O O O
to O O O O
65%. O O O O
"Even O O O O
for O O O O
those O O O O
patients O O O O
that O O O O
are O O O O
node-negative, O O O O
so O O O O
they O O O O
qualify O O O O
[for O O O O
the O O O O
trial] O O O O
based O O O O
on O O O O
the O O O O
fact O O O O
that O O O O
they O O O O
had O O O O
a O O O O
2 O O O O
cm O O O O
tumor O O O O
or O O O O
greater, O O O O
the O O O O
benefit O O O O
is O O O O
almost O O O O
6.5%," O O O O
Hamilton O O O O
said. O O O O
"And Reason 4 O O
so, Reason 4 O O
especially Reason 4 O O
for Reason 4 O O
[TNBC], Reason 4 O O
this Reason 4 O O
really Reason 4 O O
is Reason 4 O O
quite Reason 4 O O
meaningful Reason 4 O O
for Reason 4 O O
us." Reason 4 O O
Finally, O O O O
Hamilton O O O O
reviewed O O O O
data O O O O
around O O O O
adjuvant O O O O
olaparib O O O O
in O O O O
early O O O O
TNBC. O O O O
The O O O O
OlympiA O O O O
trial O O O O
investigated O O O O
olaparib O O O O
in O O O O
early O O O O
germline O O O O
BRCA O O O O
breast O O O O
cancer, O O O O
and O O O O
about O O O O
80% O O O O
of O O O O
patients O O O O
in O O O O
the O O O O
trial O O O O
did O O O O
have O O O O
TNBC O O O O
disease, O O O O
including O O O O
approximately O O O O
70% O O O O
BRCA1 O O O O
and O O O O
30% O O O O
BRCA2. O O O O
With O O O O
3.5 O O O O
years O O O O
of O O O O
median O O O O
follow O O O O
up, O O O O
the O O O O
study O O O O
found O O O O
improved O O O O
OS O O O O
of O O O O
approximately O O O O
3.4% O O O O
at O O O O
the O O O O
second O O O O
interim O O O O
analysis, O O O O
including O O O O
a O O O O
7.4% O O O O
benefit O O O O
with O O O O
both O O O O
invasive O O O O
and O O O O
distant O O O O
disease-free O O O O
survival. O O O O
As O O O O
more O O O O
studies O O O O
develop O O O O
and O O O O
new O O O O
data O O O O
are O O O O
released, O O O O
Hamilton O O O O
said O O O O
patients O O O O
with O O O O
early-stage O O O O
and O O O O
TNBC O O O O
will O O O O
continue O O O O
to O O O O
have O O O O
improved O O O O
outcomes. O O O O
Key O O O O
studies O O O O
to O O O O
watch O O O O
include O O O O
the O O O O
SASCIA O O O O
and O O O O
ASCENT-05 O O O O
trials O O O O
for O O O O
SG O O O O
in O O O O
residual O O O O
disease O O O O
post-neoadjuvant O O O O
therapy, O O O O
as O O O O
well O O O O
as O O O O
the O O O O
TROPION O O O O
Breast03 O O O O
trial O O O O
of O O O O
Dato-DXd O O O O
with O O O O
or O O O O
without O O O O
durvalumab O O O O
for O O O O
residual O O O O
disease O O O O
post-neoadjuvant O O O O
chemotherapy. O O O O
REFERENCE O O O O
Hamilton O O O O
EP. O O O O
Current O O O O
Advances: O O O O
Triple O O O O
Negative O O O O
& O O O O
Locally O O O O
Advanced O O O O
Breast O O O O
Cancer. O O O O
Presented O O O O
at: O O O O
Community O O O O
Oncology O O O O
Alliance O O O O
2023 O O O O
Meeting. O O O O
March O O O O
23, O O O O
2023 O O O O
